FOR IMMEDIATE RELEASE
Ann Arbor, MI and San Antonio, TX – May 8, 2023
Frost & Sullivan announced that it has named Genomenon® the winner of its 2023 Global Technology Innovation Leadership Award for its AI-driven genomic search engine and tech-enabled genetic expertise. Genomenon’s groundbreaking technology delivers actionable insight into the genomic drivers of genetic diseases and oncology for drug development and clinical diagnosis.
This annual award given by Frost & Sullivan recognizes the company that has developed a product with innovative features and functionality and is gaining rapid acceptance in the market.
Genomenon creates innovative solutions for both clinical diagnostic and pharmaceutical clients helping both groups navigate genomic intelligence for rare genetic diseases and oncology. Clinical diagnostic labs rely on Genomenon’s Mastermind Genomic Search Engine to find critical information to diagnose genetic diseases and identify the most appropriate patient treatment options. For pharmaceutical clients, the Genomenon scientific team leverages information in the Mastermind knowledgebase to support every stage of clients’ precision medicine pipeline, from biomarker discovery and translational testing to clinical trials and commercialization.
Tejashri Khadilkar, Frost & Sullivan industry analyst commented,
“Genomenon empowers rare disease pharmaceutical and biotechnology companies to make informed decisions about promising candidates in their pipeline and help propel novel therapeutics to market. Its commitment to innovation and creativity, scientific rigor, and accuracy, while achieving commercial success, differentiates it from competitors.”
Mike Klein, Genomenon CEO stated, “This exciting award celebrates the uniqueness of our best-in-class genetic expertise with our market-leading genomic search engine, Mastermind. These two assets enable us to drive actionable genomic insights that can save and improve the lives of those impacted by rare diseases and cancer. This award by Frost and Sullivan further validates our innovative technology for both clinical diagnostic and pharmaceutical clients and leadership in the genomics industry.”
In 2020 Frost and Sullivan awarded Genomenon as “Company of the Year”, recognizing its proven genomics methodology, interpretation and technology.
Read the complete award report here.
About Frost and Sullivan Best Practice
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.